The usefulness of CDH1 methylation as a gastric cancer peritoneal metastasis biomarker

Gastric cancer (GC) remains one of the most prevalent malignant diseases worldwide, being considered the second leading cause of global cancer deaths, affecting close to one million people per year (1). Although some recent advances in molecular biology, surgery, chemotherapy, and radiotherapy have been made, the poor prognosis and high mortality rate continue to make gastric cancer an attractive target of active clinical and basic scientific research (2).